Defining the optimum treatment regimen for azithromycin in acute tonsillopharyngitis

Pediatric Infectious Disease Journal

Volumn 23, Issue 2, 2004, Pages

  Cohen, Robert ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

Azithromycin; Group A Streptococcus; Penicillin; Pharyngitis; Tonsillopharyngitis

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN; PENICILLIN V;

ANTIBIOTIC THERAPY; BACTERIUM CULTURE; CHILDHOOD DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REGIMEN; DRUG EFFICACY; ERADICATION THERAPY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PATIENT COMPLIANCE; PENICILLIN ALLERGY; PHARYNGITIS; PRIORITY JOURNAL; RHEUMATIC FEVER; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES; TONSILLITIS; TONSILLOPHARYNGITIS; TREATMENT FAILURE;

EID: 1242343891     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000112527.33870.0d     Document Type: Conference Paper

References (57)

1. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 2002; 287:3096-102.
2. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997. Vital Health Stat 13 1999;:i-iv, 1-39.
3. Schwartz B, Marcy SM, Phillips WR, Gerber MA, Dowell SF. Pharyngitis: principles of judicious use of antimicrobial agents. Pediatrics 1998;101:171-4.
4. Bisno A, Gerber M, Gwaltney J, Kaplan E, Schwartz R. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis 2002;35: 113-25.
5. Felmingham D, Feldman C, Hryniewicz W, et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 2002;8(Suppl 2):12-42.
6. Denny FW, Wannamaker LW, Brink WR, Rammelkamp CH, Custer EA. Prevention of rheumatic fever: treatment of the preceding streptococci infection. JAMA 1950;143:151-3.
7. Wannamaker LW, Rammelkamp CH Jr, Denny FW, Brink WR, Houser HB, Hahn EO. Prophylaxis of acute rheumatic fever by treatment of preceding streptococcal infection with various amounts of depot penicillin. Am J Med 1951;10:673-95.
8. Statements of American Heart Association Council on Rheumatic Fever and Congenital Heart Disease. Protection of rheumatic fever patients. JAMA 1953;151:141-3.
9. Olivier C. Rheumatic fever: is it still a problem? J Antimicrob Chemother 2000;45:13-21.
10. Stollerman G. Rheumatic fever in the 21st century. Clin Infect Dis 2001;33:806-14.
11. Zwart S, Sachs AP, Ruijs GJ, Gubbels JW, Hoes AW, de Melker RA. Penicillin for acute sore throat: randomized double blind trial of seven days versus three days treatment or placebo in adults. BMJ 2000;320:150-4.
12. Catanzaro F, Rammelkamp J, Chamovitz R. Prevention of rheumatic fever by treatment of streptococcal infections: II. Factors responsible for failure. N Engl J Med 1958;259:51-7.
13. Lan A, Colford J, Colford JM Jr. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for tonsillopharyngitis: a meta-analysis. Pediatrics 2000;105:E19.
14. Claxton A J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
15. Gerber MA, Randolph MF, DeMeo K, Feder HM Jr, Kaplan EL. Failure of once-daily penicillin V therapy for streptococcal pharyngitis. Am J Dis Child 1989;143:153-5.
16. Pichichero M, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J 1997;16:680-95.
17. Steele RW, Estrada B, Begue RE, Mirza A, Travillion DA, Thomas MP. A double-blind taste comparison of pediatric antibiotic suspensions. Clin Pediatr (Phila) 1997;36:193-9.
18. Arreaza EE. Penicillin allergy: a review. Tex Med 1989;85: 36-43.
19. Pichichero ME. The rising incidence of penicillin treatment failures in group A streptococcal tonsillopharyngitis: an emerging role for the cephalosporins? Pediatr Infect Dis J 1991;10(Suppl):S50-5.
20. Kaplan EL, Johnson DR. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group A streptococci from children with acute pharyngitis. Pediatrics 2001;108:1180-6.
21. Ovetchkine P, Levy C, de la Rocque F, Boucherat M, Bingen E, Cohen R. Variables influencing bacteriological outcome in patients with streptococcal tonsillopharyngitis treated with penicillin V. Eur J Pediatr 2002;161:365-7.
22. Pichichero M, Casey J, Mayes T, et al. Penicillin failure in streptococcal tonsillopharyngitis: causes and remedies. Pediatr Infect Dis J 2000;19:917-23.
23. Gerber MA, Tanz RR, Kabat W, et al. Potential mechanisms for failure to eradicate group A streptococci from the pharynx. Pediatrics 1999;104:911-17.
24. Brook I. Failure of penicillin to eradicate group A beta-hemolytic streptococci tonsillitis: causes and management. J Otolaryngol 2001;30:324-9.
25. Roos K, Holm S, Grahn E, Lind L. Alpha-streptococci as supplementary treatment of recurrent streptococcal tonsillitis: a randomized placebo double blind study. Scand J Infect Dis 1993;25:31-5.
26. Kim KS, Kaplan EL. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr 1985;107:681-4.
27. Neeman R, Keller N, Barzilai A, Korenman Z, Sela S. Prevalence of internalization-associated gene, prtF1, among persisting group A Streptococcus strains isolated from asymptomatic carriers. Lancet 1998;352:1974-7.
28. Musumeci R, Bue CL, Milazzo I, et al. Internalization-associated proteins among Streptococcus pyogenes isolated from asymptomatic carriers and children with pharyngitis. Clin Infect Dis 2003;37:173-9.
29. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
30. Hand WL, Hand DL. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents 2001;18:419-25.
31. Facinelli B, Spinaci C, Magi G, Giovanetti E, Varaldo P. Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci. Lancet 2001;358:30-3.
32. Pichichero M. Short course antibiotic therapy for respiratory infections: a review of the evidence. Pediatr Infect Dis J 2000;19:929-7.
33. Adam D, Scholz H, Helmerking M. Short-course antibiotic treatment of 4782 culture-proven cases of group A streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae. J Infect Dis 2000;182:509-16.
34. McCarty J, Hedrick JA, Gooch WM. Clarithromycin suspension vs. penicillin V suspension in children with streptococcal pharyngitis. Adv Ther 2000;17:14-26.
35. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82.
36. Blandizzi C, Malizia T, Batoni G, et al. Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients. Antimicrob Agents Chemother 2002;46: 1594-6.
37. Hamil J. Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993; 31(Suppl E):89-94.
38. Weippl G. Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci. J Antimicrob Chemother 1993;31(Suppl E):95-101.
39. Still J. Management of pediatric patients with group A beta-hemolytic streptococcus pharyngitis: treatment options. Pediatr Infect Dis J 1995;14:S57-61.
40. O'Doherty B, Paediatric Azithromycin Study Group. Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Eur J Clin Microbiol Infect Dis 1996;15:718-24.
41. Pacifico L, Scopetti F, Ranucci A, Pataracchia M, Savignoni F, Chiesa, C. Comparative efficacy and safety of a 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrob Agents Chemother 1996;40:1005-8.
42. Schaad UB, Heynen G. Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group. Pediatr Infect Dis J 1996;15:791-5.
43. Venuta A, Laudizi L, Beverelli A, Bettelli F, Milioli S, Garetti E. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. J Int Med Res 1998;26:152-8.
44. Cremer J, Wallrauch C, Milatovic D, Braveny I. Azithromycin versus cefaclor in the treatment of pediatric patients with acute group A beta-hemolytic streptococcal tonsillopharyngitis. Eur J Clin Microbiol Infect Dis 1998;17:235-9.
45. Boccazzi A, Tonelli P, De Angelis M, Bellussi L, Passali D, Careddu P. Short course therapy with ceftibuten versus azithromycin in pediatric streptococcal pharyngitis. Pediatr Infect Dis J 2000;19:963-7.
46. Schaad UB, Kellerhals P, Altwegg M, The Swiss Pharyngitis Study Group. Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis. Pediatr Infect Dis J 2002;21:304-8.
47. Cohen R, Reinert P, de la Rocque F, et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute Group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2002;21:297-303.
48. Bingen E, Leclercq R, Fitoussi F, et al. Emergence of group A Streptococcus strains with different mechanisms of macrolide resistance. Antimicrob Agents Chemother 2002;46:1199-203.
49. Seppälä H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in Group A streptococci in Finland. N Engl J Med 1997;337:441-6.
50. Kaplan E, Johnson D, Del Rosario M, Horn D. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J 1999;18:1069-72.
51. Bassetti M, Manno G, Collida A, et al. Erythromycin resistance in Streptococcus pyogenes in Italy. Emerg Infect Dis 2000;6:180-3.
52. Hoban DJ. Prevalence and characterization of macrolide resistance in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America. J Chemother 2002;14(Suppl 3):25-30.
53. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant Group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002;346:1200-6.
54. Reinert RR, Lütticken R, Bryskier A, Al-Lahham A. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob Agents Chemother 2003;47:489-93.
55. Cleary P, Kaplan E, Handley J, Schlievert P. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 1992;339:518-21.
56. Seppala H, Nissinen A, Jarvinen H, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992; 326:292-7.
57. Varaldo PE, Debbia EA, Nicoletti G, et al. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Clin Infect Dis 1999;29:869-73.